Navigation Links
Xencor's XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Date:10/1/2013

MONROVIA, Calif., Oct. 1, 2013 /PRNewswire/ -- Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of XmAb®5871 in patients with active rheumatoid arthritis. XmAb5871 is the first in Xencor's class of therapeutic antibodies targeting the FcγRIIb pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion.

XmAb5871 is an Fc engineered monoclonal antibody that inhibits B cells by dual targeting CD19 and FcγRIIb. Amgen Inc. and Xencor entered into a collaboration and option agreement for XmAb5871 in December 2010. Under that agreement, Amgen has the option to acquire an exclusive worldwide license to XmAb5871, exercisable at any time before completion of a data review period following our planned subsequent Phase 2b proof-of-concept clinical trial. Xencor leads all research, development, and manufacturing activities for XmAb5871 until that time and is eligible for milestone payments.

"XmAb5871 represents a novel therapeutic strategy for engaging the FcγRIIb pathway to suppress autoimmune responses without B-cell depletion," said Bassil Dahiyat, Ph.D., president and CEO of Xencor. "This Phase 2a rheumatoid arthritis data is intended to inform a larger Phase 2 study and may support the potential use of XmAb5871 in other autoimmune diseases, such as lupus."

The Phase 2a portion of the clinical trial will evaluate biweekly doses of XmAb5871 in approximately 30 rheumatoid arthritis patients with active disease on stable non-biologic DMARD therapy. Endpoints include clinical markers of disease response.

XmAb5871 was well tolerated in the Phase 1a dose escalation part of the trial that enrolled 48 healthy male subjects and inhibited multiple biomarkers of immune function.

About Xencor, Inc.

Xencor is developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor's XmAb technology. Xencor's internally-discovered programs include XmAb5871, in Phase 2a for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.


'/>"/>
SOURCE Xencor, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sacom SPA, Leader in the Italian Green Biotechnology Fertilizer Industry, Enters the VedoGreen Financial Network
2. U.S. Blood Centers Pursue an Evolving Role in Cell Therapies
3. Blood Centers of America Experiences Record Growth
4. Verenium Enters Agreement To Be Acquired By BASF
5. CCG Investor Relations Announces Company Presenters for NexGen Life Sciences Virtual Conference
6. Independent Living Centers Play A Vital Role In Helping Students Transition Out Of High School
7. Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
8. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
9. Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.
10. 7 SynCardia Certified Centers Honored Among “Best Children’s Hospitals” for Cardiology and Heart Surgery by U.S. News & World Report
11. VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... , ... October 06, 2017 ... ... experience providing advanced instruments and applications consulting for microscopy and surface analysis, ... in application consulting, Nanoscience Analytical offers a broad range of contract analysis ...
(Date:10/7/2017)... , Oct. 6, 2017  The 2017 Nobel ... three scientists, Jacques Dubochet, Joachim Frank ... in cryo-electron microscopy (cryo-EM) have helped ... the structural biology community. The winners worked with ... now routinely produce highly resolved, three-dimensional images of ...
(Date:10/6/2017)... , ... October 06, 2017 , ... ... a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for ... Dana-Farber Cancer Institute. The event is free and open to the public, but ...
(Date:10/5/2017)... ... October 05, 2017 , ... Understanding the microbiome, the millions ... human health. Gut Love: You Are My Future, the newest exhibit on display at ... it explores the human condition through the lens of the gut microbiome. , ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):